DelveInsight’s, “Recurrent or Metastatic Head and Neck cancer Pipeline Insight, 2023,” report provides comprehensive insights about 40+ companies and 40+ pipeline drugs in Recurrent or Metastatic Head and Neck cancer pipeline landscape. It covers the Recurrent or Metastatic Head and Neck cancer pipeline drug profiles, including Recurrent or Metastatic Head and Neck cancer clinical trials and nonclinical stage products. It also covers the Recurrent or Metastatic Head and Neck cancer pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
In the Recurrent or Metastatic Head and Neck Cancer pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, Recurrent or Metastatic Head and Neck Cancer clinical trials studies, Recurrent or Metastatic Head and Neck Cancer NDA approvals (if any), and product development activities comprising the technology, Recurrent or Metastatic Head and Neck Cancer collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Key takeaways from the Recurrent or Metastatic Head and Neck Cancer Pipeline Report
- Over 40+ Recurrent or Metastatic Head and Neck Cancer companies are evaluating 40+ Recurrent or Metastatic Head and Neck Cancer pipeline therapies in various stages of development, and their anticipated acceptance in the Recurrent or Metastatic Head and Neck Cancer market would significantly increase market revenue.
- The leading Recurrent or Metastatic Head and Neck Cancer Companies includes Eisai Co Ltd, Sinocelltech, Merck, Nanobiotix, Sichuan Baili Pharmaceutical, Adlai Nortye Biopharma, BioNTech, PDS Biotechnology, Shanghai Miracogen, Incyte Corporation, Checkmate Pharmaceuticals, NATCO Pharma, Agenus, Jiangsu Hengrui Medicine, Cue Biopharma, AbbVie, and others.
- Promising Recurrent or Metastatic Head and Neck Cancer Pipeline Therapies includes pembrolizumab, methotrexate, docetaxel, cetuximab, Monalizumab, pemetrexed Vinflunine, and others.
- The Recurrent or Metastatic Head and Neck Cancer companies and academics are working to assess challenges and seek opportunities that could influence R&D Recurrent or Metastatic Head and Neck cancer. The Recurrent or Metastatic Head and Neck Cancer pipeline therapies under development are focused on novel approaches to treat/improve Recurrent or Metastatic Head and Neck cancer.
To explore more information on the latest breakthroughs in the Recurrent or Metastatic Head and Neck Cancer Pipeline treatment landscape of the report, click here @ Recurrent or Metastatic Head and Neck Cancer Pipeline Outlook
Recurrent or Metastatic Head and Neck Cancer Overview
Traditionally patients with recurrence of head and neck cancer (HNC) are considered to have poor prognosis. As a result the majority of these patients are usually treated with palliative intent or receive best supportive care. Head and neck cancers are the sixth most common cancer worldwide, and arise from the upper aerodigestive mucosa, salivary glands, and skin. Despite differences in histology and biology across cancer types, most treatment protocols are extrapolated from head and neck squamous cell carcinoma (HNSCC the most common histology. Recurrent and metastatic disease is usually incurable. There are significant gaps in knowledge. Unlike other cancer types, there are no predictive biomarkers, and no new targeted therapies have been approved for HNSCC other than cetuximab in 2006.
Recurrent or Metastatic Head and Neck cancer Emerging Drugs Profile
Xevinapant: Merck
Xevinapant is the first Inhibitor of Apoptosis Proteins antagonist with FDA Breakthrough Therapy Designation for previously untreated locally advanced squamous cell carcinoma of the head and neck, in combination with current standard of care. Merck gains exclusive global development and commercialization rights; Debiopharm to receive € 188 million upfront and up to € 710 million in regulatory and commercial milestones, as well as royalty payments
SI B001: Sichuan Baili Pharmaceutical
SI B001 is a bispecific antibody designed with the proprietary platform technology developed by Baili and SystImmune. It can bind to EGFR and HER3, and simultaneously inhibits the ligand induced EGFR×EGFR homodimers, the formation of EGFR×HER3 heterodimers and the activation of its downstreamsignal pathway. SI-B001 can also induce endocytosis of EGFR and HER3, anddown-regulate the levels of EGFR and HER3 tumor cells. In preclinical studies, SI-B001 has demonstrated superior tumor killing activities. SI-B001 Phase I trials have shown good safety and preliminary efficacy.
For further information, refer to the detailed Recurrent or Metastatic Head and Neck Cancer Unmet Needs, Recurrent or Metastatic Head and Neck Cancer Market Drivers, and Recurrent or Metastatic Head and Neck Cancer Market Barriers, click here for Recurrent or Metastatic Head and Neck Cancer Ongoing Clinical Trial Analysis
Recurrent or Metastatic Head and Neck Cancer Pipeline Therapeutics Assessment
There are approx. 40+ key companies which are developing the therapies Recurrent or Metastatic Head and Neck cancer. The companies which have their Recurrent or Metastatic Head and Neck cancer drug candidates in the most advanced stage, i.e phase III include Eisai Co
Recurrent or Metastatic Head and Neck Cancer Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
Request a sample and discover the recent advances in Recurrent or Metastatic Head and Neck Cancer Ongoing Clinical Trial Analysis and Medications, click here @ Recurrent or Metastatic Head and Neck Cancer Treatment Landscape
Scope of the Recurrent or Metastatic Head and Neck Cancer Pipeline Report
- Coverage- Global
- Recurrent or Metastatic Head and Neck CancerCompanies- Eisai Co Ltd, Sinocelltech, Merck, Nanobiotix, Sichuan Baili Pharmaceutical, Adlai Nortye Biopharma, BioNTech, PDS Biotechnology, Shanghai Miracogen, Incyte Corporation, Checkmate Pharmaceuticals, NATCO Pharma, Agenus, Jiangsu Hengrui Medicine, Cue Biopharma, AbbVie, and others.
- Recurrent or Metastatic Head and Neck CancerPipeline Therapies- pembrolizumab, methotrexate, docetaxel, cetuximab, Monalizumab, pemetrexed Vinflunine, and others.
- Recurrent or Metastatic Head and Neck Cancer Pipeline Segmentation: Phases, Mechanism of Action, Route of Administration, Product Type
Dive deep into rich insights for drugs for Recurrent or Metastatic Head and Neck Cancer Market Drivers and Recurrent or Metastatic Head and Neck Cancer Market Barriers, click here @ Recurrent or Metastatic Head and Neck Cancer Unmet Needs and Analyst Views
Table of Content
- Introduction
- Executive Summary
- Recurrent or Metastatic Head and Neck cancer: Overview
- Pipeline Therapeutics
- Therapeutic Assessment
- Recurrent or Metastatic Head and Neck cancer– DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- Lenvatinib: Eisai Co
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- SI B001: Sichuan Baili Pharmaceutical
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- Revdofilimab: AbbVie
- Drug profiles in the detailed report…..
- Early Stage Products (Preclinical)
- Drug name: Company name
- Drug profiles in the detailed report…..
- Inactive Products
- Recurrent or Metastatic Head and Neck cancer Key Companies
- Recurrent or Metastatic Head and Neck cancer Key Products
- Recurrent or Metastatic Head and Neck cancer- Unmet Needs
- Recurrent or Metastatic Head and Neck cancer- Market Drivers and Barriers
- Recurrent or Metastatic Head and Neck cancer- Future Perspectives and Conclusion
- Recurrent or Metastatic Head and Neck cancer Analyst Views
- Recurrent or Metastatic Head and Neck cancer Key Companies
- Appendix
Got Queries? Find out the related information on Recurrent or Metastatic Head and Neck Cancer Mergers and acquisitions, Recurrent or Metastatic Head and Neck Cancer Licensing Activities @ Recurrent or Metastatic Head and Neck Cancer Emerging Drugs, and Recent Trends
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
Media Contact
Company Name: DelveInsight
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV 89107
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services